A Study to Evaluate Efficacy of Different Natural Ingredients in Improving Gut Health in Adults With Leaky Gut.
NCT ID: NCT05952232
Last Updated: 2024-06-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2023-08-17
2024-05-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of a Digestive Enzyme Blend
NCT04917913
Impact of Protein Source on Gut Health
NCT05619939
Effect of Diets on the Gut Microbiota Composition and Cardiometabolic Wellbeing
NCT03539666
Effects of Pulse Consumption, Gut Microbiome, and Appetite in Healthy Participants
NCT07043712
Gastrointestinal Assessment of Three Novel RS4
NCT03255603
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PA-GH-01
1 capsule after breakfast once a day
PA-GH-01
1 capsule after breakfast once a day
MK-GH-04
1 capsule after breakfast once a day
MK-GH-04
1 capsule after breakfast once a day
TSH-GH-03
1 capsule after breakfast once a day
TSH-GH-03
1 capsule after breakfast once a day
PA-GH-02
1 capsule after breakfast once a day
PA-GH-02
1 capsule after breakfast once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PA-GH-01
1 capsule after breakfast once a day
MK-GH-04
1 capsule after breakfast once a day
TSH-GH-03
1 capsule after breakfast once a day
PA-GH-02
1 capsule after breakfast once a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index \> 18 and \< 29.9 kg/m2
* Individuals with at least once/ week complains of ≥ 3 of following gastrointestinal symptoms since last three months: dyspepsia, diarrhea, constipation, heartburn, nausea, acid reflux, bloating.
* Individuals agreeing to consume four tablets (325 mg each) of aspirin twice within a 12-hour period
* Individuals with fasting blood glucose levels ≤ 125 mg/dL
* Individuals with availability of western toilet at their homes for stool sample collection
* Individuals who are literate enough to understand the essence of study, are informed about the purpose of the study, and understand their rights.
* Individuals who are able to give written informed consent and are willing to participate in the study.
Exclusion Criteria
* Allergy to aspirin
* Use of medications in the last 2 weeks prior to the pre-baseline period. This does not include birth control pills or standard multi-vitamin/mineral supplements
* Performing high intensity exercise regularly using IPAQ- SF
* Daily use of NSAIDs in the last 3 months or incidental use in the last 2 weeks prior to screening
* Unwillingness to avoid the use of antidiarrheal or laxative medication on a regular or an "as-needed basis" during the full length of the study
* Abnormal Thyroid Stimulating Hormone (TSH) value which is \< 0.40 or \> 4.50 μIU/mL
* Individuals with uncontrolled type II DM defined as FBG \> 125 mg/ dL
* Presence of uncontrolled hypertension defined as SBP ≥ 140 mm Hg and/or DBP ≥ 90 mm Hg with or without anti-hypertensives
* Individuals on high-fiber/ fodmap diet
* Individuals with known diagnosis of helicobacter pylori infection
* Individuals with a history of surgical resection of the stomach, small intestine or large intestine
* Individuals with a history of or complications from inflammatory bowel disease (Crohn's disease or ulcerative colitis) and ischemic colitis
* Current smokers
* Use of another investigational product within 3 months of the screening visit
* History or current impaired cardiovascular circulation or uncontrolled hypertension, diabetes, bleeding tendencies, kidney, liver or chronic respiratory diseases including asthma, or any other disease, that by the investigators' discretion could interfere with the intestinal barrier function of the subject
* Individuals who used probiotics, prebiotics, antibiotics, prokinetics, laxatives, suppositories or enemas in the last 3 months
* Individuals with a history of any diet-based intolerance (gluten or lactose intolerance)
* Individuals with a history of or complications from malignant tumors.
* History of any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
* Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/Nicotine dependence.
* High-risk drinking as defined by consumption of 4 or more alcohol containing beverages on any day or 8 or more alcohol containing beverages per week for women and 5 or more alcohol containing beverages on any day or 15 or more alcohol containing beverages per week for men
* Individuals who have clinically significant following illness, i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, other gastrointestinal diseases, etc
* Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives
* Any condition that could, in the opinion of the investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Kumta Mali's Clinic
Mumbai, Maharashtra, India
Dr. Preeti Bawaskar's Clinic
Thāne, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EB/230301/TPEKC/LG
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.